{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:55:44Z","timestamp":1794333344251,"version":"4.9.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous disease characterized by a high risk of transformation to invasive oral squamous cell carcinoma (OSCC), and no therapies have been shown to affect its natural history. A recent study of the PVL immune landscape revealed a cytotoxic T-cell\u2013rich microenvironment, providing strong rationale to investigate immune checkpoint therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the safety and clinical activity of anti\u2013programmed cell death 1 protein (PD-1) therapy to treat high-risk PVL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This nonrandomized, open-label, phase 2 clinical trial was conducted from January 2019 to December 2021 at a single academic medical center; median (range) follow-up was 21.1 (5.4-43.6) months. Participants were a population-based sample of patients with PVL (multifocal, contiguous, or a single lesion \u22654 cm with any degree of dysplasia).<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Patients underwent pretreatment biopsy (1-3 sites) and then received 4 doses of nivolumab (480 mg intravenously) every 28 days, followed by rebiopsy and intraoral photographs at each visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was the change in composite score (size and degree of dysplasia) from before to after treatment (major response [MR]: &amp;amp;gt;80% decrease in score; partial response: 40%-80% decrease). Secondary analyses included immune-related adverse events, cancer-free survival (CFS), PD-1 ligand 1 (PD-L1) expression, 9p21.3 deletion, and other exploratory immunologic and genomic associations of response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 patients were enrolled (median [range] age, 63 [32-80] years; 18 [55%] were female), including 8 (24%) with previously resected early-stage OSCC. Twelve patients (36%) (95% CI, 20.4%-54.8%) had a response by composite score (3 MRs [9%]), 4 had progressive disease (&amp;amp;gt;10% composite score increase, or cancer). Nine patients (27%) developed OSCC during the trial, with a 2-year CFS of 73% (95% CI, 53%-86%). Two patients (6%) discontinued because of toxic effects; 7 (21%) experienced grade 3 to 4 immune-related adverse events. PD-L1 combined positive scores were not associated with response or CFS. Of 20 whole-exome sequenced patients, all 6 patients who had progression to OSCC after nivolumab treatment exhibited 9p21.3 somatic copy-number loss on pretreatment biopsy, while only 4 of the 14 patients (29%) who did not develop OSCC had 9p21.3 loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This immune checkpoint therapy precancer nonrandomized clinical trial met its prespecified response end point, suggesting potential clinical activity for nivolumab in high-risk PVL. Findings identified immunogenomic associations to inform future trials in this precancerous disease with unmet medical need that has been difficult to study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03692325\">NCT03692325<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.4853","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:01:06Z","timestamp":1700150466000},"page":"32","source":"Crossref","is-referenced-by-count":68,"title":["Nivolumab for Patients With High-Risk Oral Leukoplakia"],"prefix":"10.1001","volume":"10","author":[{"given":"Glenn J.","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute and Herbert Wertheim College of Medicine, Florida International University, Miami"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvro P.","family":"Nandi","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, California"},{"name":"Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"ONeill","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mofei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Treister","sequence":"additional","affiliation":[{"name":"Division of Oral Medicine and Dentistry, Dana-Farber Cancer Institute and Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve Y.","family":"Sroussi","sequence":"additional","affiliation":[{"name":"Division of Oral Medicine and Dentistry, Dana-Farber Cancer Institute and Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piamkamon","family":"Vacharotayangul","sequence":"additional","affiliation":[{"name":"Division of Oral Medicine and Dentistry, Dana-Farber Cancer Institute and Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Goguen","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Brigham & Women\u2019s Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Donald J.","family":"Annino","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Brigham & Women\u2019s Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni M.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Brigham & Women\u2019s Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie Y.","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine S.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lizotte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Uppaluri","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Brigham & Women\u2019s Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E. W.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmil B.","family":"Alexandrov","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, California"},{"name":"Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, California"},{"name":"Department of Bioengineering, UC San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"William N.","family":"William","sequence":"additional","affiliation":[{"name":"Oncology Center, Hospital BP, a Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-bin","family":"Woo","sequence":"additional","affiliation":[{"name":"Division of Oral Medicine and Dentistry, Dana-Farber Cancer Institute and Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi230062r1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/jop.2018.47.issue-7","article-title":"Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis.","volume":"47","author":"Mello","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"10","key":"coi230062r2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/jnci\/djz238","article-title":"Oral leukoplakia and risk of progression to oral cancer: a population-based cohort study.","volume":"112","author":"Chaturvedi","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"coi230062r3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.oooo.2017.12.011","article-title":"Oral potentially malignant disorders: risk of progression to malignancy.","volume":"125","author":"Speight","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"coi230062r4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/jop.v49.5","article-title":"Clinical manifestations of oral proliferative verrucous leukoplakia: a systematic review.","volume":"49","author":"Torrejon-Moya","year":"2020","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"coi230062r5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/odi.2018.24.issue-5","article-title":"Proliferative leukoplakia: proposed new clinical diagnostic criteria.","volume":"24","author":"Villa","year":"2018","journal-title":"Oral Dis"},{"issue":"4","key":"coi230062r6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/lio2.v6.4","article-title":"An active surveillance program in oral preneoplasia and translational oncology benefit.","volume":"6","author":"Archibald","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"2","key":"coi230062r7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial.","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi230062r8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJM199301073280103","article-title":"Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.","volume":"328","author":"Lippman","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"coi230062r9","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1158\/1078-0432.CCR-07-4024","article-title":"Pilot randomized phase II study of celecoxib in oral premalignant lesions.","volume":"14","author":"Papadimitrakopoulou","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10167","key":"coi230062r10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"10212","key":"coi230062r11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"coi230062r12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"coi230062r13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi230062r14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/2767-9764.CRC-21-0060","article-title":"Comprehensive immunoprofiling of high-risk oral proliferative and localized leukoplakia.","volume":"1","author":"Hanna","year":"2021","journal-title":"Cancer Res Commun"},{"issue":"39","key":"coi230062r15","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1608077113","article-title":"Leveraging premalignant biology for immune-based cancer prevention.","volume":"113","author":"Spira","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7766","key":"coi230062r16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","article-title":"Immune evasion before tumour invasion in early lung squamous carcinogenesis.","volume":"571","author":"Mascaux","year":"2019","journal-title":"Nature"},{"issue":"10","key":"coi230062r17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/2159-8290.CD-19-1366","article-title":"Immune surveillance in clinical regression of preinvasive squamous cell lung cancer.","volume":"10","author":"Pennycuick","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"coi230062r18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/2159-8290.CD-20-1087","article-title":"Immunosurveillance and regression in the context of squamous pulmonary premalignancy.","volume":"10","author":"Krysan","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"coi230062r19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1368-8375(99)00092-5","article-title":"A modified classification and staging system for oral leukoplakia.","volume":"36","author":"van der Waal","year":"2000","journal-title":"Oral Oncol"},{"issue":"1","key":"coi230062r21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"coi230062r22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"19","key":"coi230062r23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022655118","article-title":"Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss.","volume":"118","author":"William","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"coi230062r24","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 Loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"coi230062r25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.oraloncology.2014.11.002","article-title":"Prevention of head and neck squamous cell carcinoma: removing the \u201cchemo\u201d from \u201cchemoprevention\u201d.","volume":"51","author":"Saba","year":"2015","journal-title":"Oral Oncol"},{"issue":"24","key":"coi230062r26","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1200\/JCO.2003.03.544","article-title":"An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.","volume":"21","author":"Rudin","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi230062r27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.2008.17.1850","article-title":"Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.","volume":"27","author":"Papadimitrakopoulou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi230062r28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1158\/1078-0432.CCR-1020-3","article-title":"Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.","volume":"10","author":"Mulshine","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"coi230062r29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/0194599815586779","article-title":"Optimal management of proliferative verrucous leukoplakia: a systematic review of the literature.","volume":"153","author":"Abadie","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"coi230062r30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.2014.170.issue-5","article-title":"Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? a systematic review.","volume":"170","author":"Pentenero","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"coi230062r31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41379-022-01021-x","article-title":"Characterization of initial\/early histologic features of proliferative leukoplakia and correlation with malignant transformation: a multicenter study.","volume":"35","author":"Alabdulaaly","year":"2022","journal-title":"Mod Pathol"},{"issue":"2","key":"coi230062r32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12105-020-01262-9","article-title":"Proliferative verrucous leukoplakia: an expert consensus guideline for standardized assessment and reporting.","volume":"15","author":"Thompson","year":"2021","journal-title":"Head Neck Pathol"},{"issue":"11","key":"coi230062r33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.oraloncology.2015.08.009","article-title":"Elective versus therapeutic neck dissection in node-negative oral cancer: evidence from five randomized controlled trials.","volume":"51","author":"Ren","year":"2015","journal-title":"Oral Oncol"},{"issue":"2","key":"coi230062r34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0964-1955(92)90035-Y","article-title":"Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR): preliminary results.","volume":"28B","author":"Chiesa","year":"1992","journal-title":"Eur J Cancer B Oral Oncol"},{"issue":"8","key":"coi230062r35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/1940-6207.CAPR-15-0390","article-title":"A randomized double-blind placebo-controlled phase IIB trial of curcumin in oral leukoplakia.","volume":"9","author":"Kuriakose","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"coi230062r36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2004.09.021","article-title":"The convergence of cancer prevention and therapy in early-phase clinical drug development.","volume":"6","author":"Abbruzzese","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"coi230062r37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41591-018-0323-0","article-title":"Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.","volume":"25","author":"Teixeira","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"coi230062r38","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/0008-5472.CAN-16-2346","article-title":"Precancer atlas to drive precision prevention trials.","volume":"77","author":"Spira","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"coi230062r39","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1055-9965.EPI-08-0574","article-title":"Frequent alterations of p16INK4a? and p14ARF in oral proliferative verrucous leukoplakia.","volume":"17","author":"Kresty","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"47","key":"coi230062r40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213835119","article-title":"Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"coi230062r41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","article-title":"Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy.","volume":"6","author":"Ebot","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"coi230062r42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis.","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"coi230062r43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13073-022-01138-3","article-title":"Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution.","volume":"14","author":"Thol","year":"2022","journal-title":"Genome Med"},{"issue":"5","key":"coi230062r44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/cncr.v129.5","article-title":"Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.","volume":"129","author":"William","year":"2023","journal-title":"Cancer"},{"key":"coi230062r45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.oraloncology.2019.06.032","article-title":"Immune profiles in primary squamous cell carcinoma of the head and neck.","volume":"96","author":"Saloura","year":"2019","journal-title":"Oral Oncol"},{"key":"coi230062r20","author":"National Cancer Institute","year":"2017"},{"key":"coi230062r46","unstructured":"Pembrolizumab in treating participants with leukoplakia. ClinicalTrials.gov identifier: NCT03603223. Updated June 15, 2023. Accessed October 10, 2023. https:\/\/clinicaltrials.gov\/study\/NCT03603223"},{"key":"coi230062r47","unstructured":"Immune checkpoint inhibitor in high risk oral premalignant lesions (IMPEDE). ClinicalTrials.gov identifier: NCT04504552. Updated December 1, 2020. Accessed October 10, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04504552"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2811991\/jamaoncology_hanna_2023_oi_230062_1704491788.37177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:01:40Z","timestamp":1705593700000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2811991"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.4853","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}